Marisa Winkler

2.7k total citations
30 papers, 951 citations indexed

About

Marisa Winkler is a scholar working on Molecular Medicine, Epidemiology and Pharmacology. According to data from OpenAlex, Marisa Winkler has authored 30 papers receiving a total of 951 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Medicine, 13 papers in Epidemiology and 11 papers in Pharmacology. Recurrent topics in Marisa Winkler's work include Antibiotic Resistance in Bacteria (20 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Antibiotic Use and Resistance (6 papers). Marisa Winkler is often cited by papers focused on Antibiotic Resistance in Bacteria (20 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Antibiotic Use and Resistance (6 papers). Marisa Winkler collaborates with scholars based in United States, Italy and Switzerland. Marisa Winkler's co-authors include Robert A. Bonomo, Krisztina M. Papp‐Wallace, Magdalena A. Taracila, Andrea M. Hujer, Yan Xu, Tatiana Domitrovic, Brad Spellberg, Marion J. Tuohy, Kelly Hurless and Kristine M. Hujer and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Marisa Winkler

27 papers receiving 932 citations

Peers

Countries citing papers authored by Marisa Winkler

Since Specialization

Citations

This map shows the geographic impact of Marisa Winkler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marisa Winkler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marisa Winkler more than expected).

Fields of papers citing papers by Marisa Winkler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marisa Winkler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marisa Winkler. The network helps show where Marisa Winkler may publish in the future.

Co-authorship network of co-authors of Marisa Winkler

This figure shows the co-authorship network connecting the top 25 collaborators of Marisa Winkler. A scholar is included among the top collaborators of Marisa Winkler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marisa Winkler. Marisa Winkler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Activity of Rezafungin Against Echinocandin Non–wild type Candida glabrata Clinical Isolates From a Global Surveillance Program 2025 ·Open Forum Infectious Diseases ·Mariana Castanheira, Lalitagauri M. Deshpande, John H. Kimbrough, Marisa Winkler	0
2	Antimicrobial susceptibility of clinical isolates of Stenotrophomonas maltophilia from Europe, Asia, and Latin America (2018-2023) 2025 ·International Journal of Infectious Diseases ·Hélio S. Sader, Rodrigo E. Mendes, Timothy B Doyle, Marisa Winkler, (unknown)	1
3	Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019–2023) 2025 ·Journal of Antimicrobial Chemotherapy ·Hélio S. Sader, John H. Kimbrough, Marisa Winkler, Mariana Castanheira, Rodrigo E. Mendes	2
4	Impact of MIC Breakpoint Changes for Enterobacterales on Trends of Antibiotic Susceptibilities in An Academic Medical Center 2024 ·SHILAP Revista de lepidopterología ·David Evans, Marisa Winkler, Eileen M. Burd, Ashley Jones, (unknown), James P. Steinberg, Jesse T. Jacob	0
5	Use of voriconazole to predict susceptibility and resistance to isavuconazole for Aspergillus fumigatus using CLSI methods and interpretive criteria 2024 ·Journal of Clinical Microbiology ·Marisa Winkler, Paul R. Rhomberg, (unknown), Michael D. Huband, (unknown), John H. Kimbrough, Mariana Castanheira	2
6	The In Vitro Activity of Rezafungin Against Uncommon Species of Candida 2024 ·Mycoses ·Marisa Winkler, Paul R. Rhomberg, (unknown), (unknown), (unknown)	4
7	A decade of clinical microbiology: top 10 advances in 10 years: what every infection preventionist and antimicrobial steward should know 2024 ·SHILAP Revista de lepidopterología ·Tulip A. Jhaveri, Zoe Weiss, Marisa Winkler, (unknown), Sankha S. Basu, Nicole Pecora	7
8	If you don’t test, they will not treat: Impact of stopping preoperative screening for asymptomatic bacteriuria 2023 ·SHILAP Revista de lepidopterología ·Marisa Winkler, Joanne Huang, (unknown), David C. Hooper, Molly L Paras, Alyssa R. Letourneau, Erica S. Shenoy	3
9	Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant β-Lactamases and Their Increasing Importance 2022 ·Antimicrobial Agents and Chemotherapy ·Andrea M. Hujer, Christopher R. Bethel, Magdalena A. Taracila, Steven H. Marshall, Laura J. Rojas, Marisa Winkler, Ronald E. Painter, Tatiana Domitrovic, Richard Watkins, Ayman M. Abdelhamed, Roshan D’Souza, Andrew R Mack, Richard C. White, Thomas H. Clarke, Derrick E. Fouts, Michael R. Jacobs, Katherine Young, Robert A. Bonomo	14
10	Infection Prevention and Control of Severe Acute Respiratory Syndrome Coronavirus 2 in Health Care Settings 2022 ·Infectious Disease Clinics of North America ·Marisa Winkler, David C. Hooper, Erica S. Shenoy	4
11	Empirical Assessment of U.S. Coronavirus Disease 2019 Crisis Standards of Care Guidelines 2021 ·Critical Care Explorations ·Maheetha Bharadwaj, (unknown), Sandeep P. Kishore, Marisa Winkler, (unknown), (unknown), Conor Crowley, Mayra Pinilla-Vera, Jack Varon, Rebecca M. Baron, William B. Feldman, Edy Y. Kim	3
12	Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients 2017 ·ACS Infectious Diseases ·Krisztina M. Papp‐Wallace, Scott A. Becka, (unknown), (unknown), María F. Mojica, (unknown), Monica Falleni, Delfina Tosi, Elisa Borghi, Marisa Winkler, Brigid Wilson, John J. LiPuma, Michiyoshi Nukaga, Robert A. Bonomo	53
13	Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering 2017 ·mBio ·Melissa D. Barnes, Marisa Winkler, Magdalena A. Taracila, Malcolm G. P. Page, Eric Desarbre, Barry N. Kreiswirth, Ryan K. Shields, (unknown), Cornelius J. Clancy, Brad Spellberg, Krisztina M. Papp‐Wallace, Robert A. Bonomo	107
14	Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases 2015 ·Diagnostic Microbiology and Infectious Disease ·Krisztina M. Papp‐Wallace, Saralee Bajaksouzian, Ayman M. Abdelhamed, (unknown), Marisa Winkler, (unknown), Wright W. Nichols, Raymond T. Testa, Robert A. Bonomo, Michael R. Jacobs	40
15	Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop 2015 ·Journal of Antimicrobial Chemotherapy ·Marisa Winkler, Krisztina M. Papp‐Wallace, Robert A. Bonomo	113
16	Exposing a β-Lactamase “Twist”: the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase 2015 ·Antimicrobial Agents and Chemotherapy ·Krisztina M. Papp‐Wallace, Scott A. Becka, Magdalena A. Taracila, Marisa Winkler, (unknown), Drew A. Rholl, Herbert P. Schweizer, Robert A. Bonomo	24
17	SHV-129: A Gateway to Global Suppressors in the SHV β-Lactamase Family? 2015 ·Molecular Biology and Evolution ·Marisa Winkler, Robert A. Bonomo	10
18	Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa 2014 ·Antimicrobial Agents and Chemotherapy ·Marisa Winkler, Krisztina M. Papp‐Wallace, Andrea M. Hujer, Tatiana Domitrovic, Kristine M. Hujer, Kelly Hurless, Marion J. Tuohy, Géraldine Hall, Robert A. Bonomo	121
19	Exploring the Role of a Conserved Class A Residue in the Ω-Loop of KPC-2 β-Lactamase 2012 ·Journal of Biological Chemistry ·(unknown), Krisztina M. Papp‐Wallace, Magdalena A. Taracila, Andrea M. Hujer, Marisa Winkler, Kerri M. Smith, Yan Xu, Michael E. Harris, Robert A. Bonomo	83
20	Design and Exploration of Novel Boronic Acid Inhibitors Reveals Important Interactions with a Clavulanic Acid-Resistant Sulfhydryl-Variable (SHV) β-Lactamase 2012 ·Journal of Medicinal Chemistry ·Marisa Winkler, (unknown), Magdalena A. Taracila, Sarah M. Drawz, Christopher R. Bethel, Krisztina M. Papp‐Wallace, Kerri M. Smith, Yan Xu, (unknown), Chiara Romagnoli, Emilia Caselli, Fabio Prati, Focco van den Akker, Robert A. Bonomo	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact